IMPLQ — IPI Legacy Liquidation Co Share News
0.000.00%
Last trade - 00:00- $0.36m
- $0.12m
- $12.65m
U.S. FDA approves Impel NeuroPharma's acute migraine treatment
NASDAQ TRADE HALT HALT NEWS PENDING AT 08:25 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:35 AM
Impel Neuropharma Inc reports results for the quarter ended in June - Earnings Summary
Brief: Impel Neuropharma Announces Q2 Non-GAAP Loss Per Share Of $0.79
Brief: Impel Neuropharma Announces Publication Of Pivotal Phase 3, Open-Label Stop 301 Study Of Inp104 (Trudhesa) For Treatment Of Acute Migraine In Journal Headache
Brief: Impel Neuropharma Says Entered Into A Loan And Security Agreement With Oxford Finance Llc And Silicon Valley Bank
Brief: Impel Neuropharma Announces First Quarter 2021 Financial Results And Provides Business Update
Impel Neuropharma Inc reports results for the quarter ended in March - Earnings Summary
Brief: 5Am Ventures V L.P. Reports 11.9% Passive Stake In Impel Neuropharma Inc, As Of April 27, 2021
Brief: Impel Neuropharma Inc Shares Open 2.1% Above IPO Price In Nasdaq Debut
NASDAQ RESUMED AT 11:44 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
Brief: Impel Neuropharma Announces Pricing Of $80.0 Million Initial Public Offering
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:00 AM
Live Markets: IPOs wade into choppy waters
Brief: Impel Neuropharma Inc Sees IPO Of Up To 5.33 Million Shares Of Common Stock Priced To Be Between $14.00 And $16.00 Per Share